All In Biotech

NDA 210282 · Hospira

Daptomycin

Daptomycin · Intravenous · Lipopeptide Antibacterial

Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jun 21, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

94

20 Phase 3, 4 recruiting

FAERS reports

9,502

8,805 serious, 1,286 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 8, 2026.

Daptomycin for Injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult patients ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) Limitations of Use: • This Daptomycin for Injection product is not approved for use in pediatric patients. ( 1.3 ) • Daptomycin for Injection is not indicated for the treatment of pneumonia. ( 1.3 ) • Daptomycin for Injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus . ( 1.3 ) • Daptomycin for Injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Daptomycin for Injection and other antibacterial drugs, Daptomycin for Injection should be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 ) 1.1 Complicated Skin and Skin Structure Infections (cSSSI) Daptomycin for Injection is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia) in Adult Patients, Including Those with Right-Sided...

Mechanism: Daptomycin is an antibacterial drug [see Clinical Pharmacology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 21, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
2 products under this application
  • DAPTOMYCIN · DAPTOMYCIN 350MG/VIAL · POWDER, INTRAVENOUS · Prescription
  • DAPTOMYCIN · DAPTOMYCIN 500MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Daptomycin" as an intervention, any sponsor and status, largest first.

All 94 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective768
  • off label use703
  • acute kidney injury628
  • eosinophilic pneumonia487
  • pyrexia481
  • rhabdomyolysis389
  • eosinophilia387
  • drug reaction with eosinophilia and systemic symptoms344
  • blood creatine phosphokinase increased329
  • product use in unapproved indication321
  • neutropenia302
  • thrombocytopenia288

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200521
200622
200723
200831
200978
201067
201187
2012121
2013117
2014128
2015319
2016237
2017307
2018595
2019491
2020665
2021836
2022899
20231,100
20241,107
20251,182
20261,059

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Daptomycin (Daptomycin)

2024 spending

$121M

Beneficiaries

35,354

152,673 claims

Per beneficiary

$3,413

$50.13 per unit

View as table
YearSpending
2020$127,610,426
2021$138,049,141
2022$136,231,454
2023$132,828,478
2024$120,655,233

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 153 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.